ID   CLL-1390
AC   CVCL_DI61
SY   CLL1390
DR   GEO; GSM1974780
DR   Wikidata; Q54813639
RX   PubMed=15746063;
RX   PubMed=22236332;
RX   PubMed=27197945;
RX   PubMed=27257868;
RX   PubMed=31175136;
CC   Part of: FACC canine tumor cell line panel.
CC   Doubling time: 37 hours (PubMed=27257868).
CC   Sequence variation: Mutation; VGNC; VGNC:39069; CDKN1B; Simple; p.Ter199fs (c.596_597insCC); Zygosity=Homozygous (PubMed=31175136).
CC   Sequence variation: Mutation; VGNC; VGNC:54168; KDM6A; Simple; p.Val1131fs (c.3390delCinsGGG); Zygosity=Homozygous (PubMed=31175136).
CC   Sequence variation: Mutation; VGNC; VGNC:47261; TET2; Simple; p.Gln965Ter (c.2893C>T); Zygosity=Homozygous (PubMed=31175136).
CC   Sequence variation: Mutation; VGNC; VGNC:47719; TP53; Simple; p.Asp60fs (c.176_177insAAGGGAGCTTGAAGGTTTCT); Zygosity=Heterozygous (PubMed=31175136).
CC   Omics: Genomics; Whole exome sequencing.
CC   Omics: Transcriptomics; Microarray.
CC   Omics: Variations; Array-based CGH.
CC   Omics: Variations; CNV analysis.
ST   Source(s): PubMed=27197945; PubMed=31175136
ST   Dog FHC2010: 235,239
ST   Dog FHC2054: 151,172
ST   Dog FHC2079: 275
ST   Dog PEZ1: 111,119
ST   Dog PEZ3: 115,131
ST   Dog PEZ5: 107,115
ST   Dog PEZ6: 176,179
ST   Dog PEZ8: 240
ST   Dog PEZ12: 263,271
ST   Dog PEZ20: 176,180
DI   NCIt; C128120; Canine leukemia
OX   NCBI_TaxID=9615; ! Canis lupus familiaris (Dog)
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 13-07-16; Last updated: 10-04-25; Version: 10
//
RX   PubMed=15746063; DOI=10.1158/1078-0432.CCR-04-1944;
RA   Suter S.E., Chein M.B., von Messling V., Yip B., Cattaneo R.,
RA   Vernau W., Madewell B.R., London C.A.;
RT   "In vitro canine distemper virus infection of canine lymphoid cells: a
RT   prelude to oncolytic therapy for lymphoma.";
RL   Clin. Cancer Res. 11:1579-1587(2005).
//
RX   PubMed=22236332; DOI=10.1111/j.1476-5829.2011.00299.x;
RA   Seiser E.L., Thomas R., Richards K.L., Kelley M.K., Moore P.,
RA   Suter S.E., Breen M.;
RT   "Reading between the lines: molecular characterization of five widely
RT   used canine lymphoid tumour cell lines.";
RL   Vet. Comp. Oncol. 11:30-50(2013).
//
RX   PubMed=27197945; DOI=10.1111/vco.12192; PMCID=PMC5656225;
RA   Fowles J.S., Dailey D.D., Gustafson D.L., Thamm D.H., Duval D.L.;
RT   "The Flint Animal Cancer Center (FACC) canine tumour cell line panel:
RT   a resource for veterinary drug discovery, comparative oncology and
RT   translational medicine.";
RL   Vet. Comp. Oncol. 15:481-492(2017).
//
RX   PubMed=27257868; DOI=10.1371/journal.pone.0156689; PMCID=PMC4892608;
RA   Maeda J., Froning C.E., Brents C.A., Rose B.J., Thamm D.H., Kato T.A.;
RT   "Intrinsic radiosensitivity and cellular characterization of 27 canine
RT   cancer cell lines.";
RL   PLoS ONE 11:e0156689.1-e0156689.18(2016).
//
RX   PubMed=31175136; DOI=10.1158/1535-7163.MCT-18-1346; PMCID=PMC6679748;
RA   Das S., Idate R., Cronise K.E., Gustafson D.L., Duval D.L.;
RT   "Identifying candidate druggable targets in canine cancer cell lines
RT   using whole-exome sequencing.";
RL   Mol. Cancer Ther. 18:1460-1471(2019).
//